IP Library › Granted Patent US 11,851,495
Granted Patent B2
US 11,851,495 · App. 17/084,881 · Granted Dec 26, 2023

TRAILR2 CDH17 binding molecules for the treatment of cancer

Inventors: Klaus-Peter Kuenkele (Langenbach, DE); Timothy Fenn (Greenwich, CT); Juan Manuel Garcia-Martinez (Vienna, AT); Jason Ho (Collegeville, PA); Christian Koessl (Kramsach, AT); Saurabh Sen (Sandy Hook, CT); Vladimir Voynov (Danbury, CT); Andreas Wernitznig (Vienna, AT)
Assignee: Boehringer Ingelheim International GmbH
C07K16/2866A61P35/00C07K16/28C07K16/2878A61K2039/505C07K2317/14C07K2317/31C07K2317/35C07K2317/622C07K2317/64C07K2317/73
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,851,495
App. No.
17/084,881
Granted
Dec 26, 2023
Kind
B2
Abstract

This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.

Claims (45)

1. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a binding molecule that binds to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17), said binding molecule comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:196 or SEQ ID NO:197; and a light chain comprising the amino acid sequence of SEQ ID NO:203, wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.

2. The method of claim 1 , wherein the cancer is pancreatic cancer (PAC).

3. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a binding molecule that binds to TRAILR2 and CDH17, said binding molecule comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:211 or SEQ ID NO:212; and a light chain comprising the amino acid sequence of SEQ ID NO:218, wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.

4. The method of claim 3 , wherein the cancer is pancreatic cancer (PAC).

5. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a binding molecule comprising at least one agonistic antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and at least one antigen binding site that binds specifically to cadherin-17 (CDH17), wherein said at least one antigen binding site that binds specifically to TRAILR2 comprises heavy chain CDRs comprising SEQ ID NO:43 (CDR1), SEQ ID NO:44 (CDR2) and SEQ ID NO:48 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO:49 (CDR1), SEQ ID NO:50 (CDR2) and SEQ ID NO:54 (CDR3), and

wherein said at least one antigen binding site that binds specifically to CDH17 comprises heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:70 (CDR1), SEQ ID NO: 71 (CDR2) and SEQ ID NO:72 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO:73 (CDR1), SEQ ID NO:74 (CDR2) and SEQ ID NO:75 (CDR3), wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.

6. The method of claim 5 , wherein said binding molecule is bispecific and tetravalent.

7. The method of claim 5 , wherein said at least one antigen binding site that binds specifically to cadherin-17 (CDH17) is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) comprises one or more scFv(s).

8. The method of claim 7 , wherein said one or more scFv(s) have a VL-VH orientation from N- to C-terminus.

9. The method of claim 7 , wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule.

10. The method of claim 7 , wherein the Ig molecule is IgG.

11. The method of claim 7 , wherein the one or more scFv(s) is fused to the Ig molecule by a peptide linker.

12. The method of claim 11 , wherein the peptide linker has a length of about 4 to 20 amino acids.

13. The method of claim 5 , wherein the antigen binding site that binds specifically to CDH17 comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:114 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:115; or comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:116 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:117.

14. The method of claim 5 , wherein the cancer is pancreatic cancer (PAC).

15. The method of claim 5 , wherein the antigen binding site that binds specifically to TRAILR2 comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:96 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:97; or comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:98 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:99.

16. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a binding molecule comprising at least one antigen binding site that binds specifically to TRAILR2 and at least one antigen binding site that binds specifically to CDH17, wherein the antigen binding site that binds specifically to TRAILR2 and the antigen binding site that binds specifically to CDH17 comprise:

a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:96 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:97, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:114 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:115, respectively;

or

a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:96 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:97, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:116 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:117, respectively;

or

a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:98 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:99, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:114 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:115, respectively;

or

a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:98 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:99, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:116 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:117, respectively,

wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.

17. The method of claim 16 , wherein the binding molecule is bispecific and tetravalent.

18. The method of claim 16 , wherein the at least one antigen binding site that binds specifically to CDH17 is an immunoglobulin (Ig) molecule and the at least one antigen binding site that binds specifically to TRAILR2 comprises one or more scFv(s).

19. The method of claim 18 , wherein the one or more scFv(s) have a VL-VH orientation from N- to C-terminus.

20. The method of claim 18 , wherein the one or more scFv(s) is fused to the C-terminus of the heavy chain of the Ig molecule.

21. The method of claim 18 , wherein the Ig molecule is IgG.

22. The method of claim 18 , wherein the one or more scFv(s) is fused to the Ig molecule by a peptide linker.

23. The method of claim 22 , wherein the peptide linker has a length of about 4 to 20 amino acids.

24. The method of claim 16 , wherein the cancer is pancreatic cancer (PAC).

25. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a binding molecule that binds to TRAILR2 and CDH17, said binding molecule comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:196 or SEQ ID NO:197; and a light chain comprising the amino acid sequence of SEQ ID NO:203, wherein said cancer expresses TRAILR2 and CDH17.

26. The method of claim 25 , wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.

27. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a binding molecule that binds to TRAILR2 and CDH17, said binding molecule comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:211 or SEQ ID NO:212; and a light chain comprising the amino acid sequence of SEQ ID NO:218, wherein said cancer expresses TRAILR2 and CDH17.

28. The method of claim 27 , wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.

29. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a binding molecule comprising at least one antigen binding site that binds specifically to TRAILR2 and at least one antigen binding site that binds specifically to CDH17, wherein said binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO:196 and (ii) a light chain comprising the amino acid sequence of SEQ ID NO:203, wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.

30. The method of claim 29 , wherein the cancer is pancreatic cancer (PAC).

31. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a binding molecule comprising at least one antigen binding site that binds specifically to TRAILR2 and at least one antigen binding site that binds specifically to CDH17, wherein said binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO:197 and (ii) a light chain comprising the amino acid sequence of SEQ ID NO:203, wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.

32. The method of claim 31 , wherein the cancer is pancreatic cancer (PAC).

33. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a binding molecule comprising at least one antigen binding site that binds specifically to TRAILR2 and at least one antigen binding site that binds specifically to CDH17, wherein said binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO:211 and (ii) a light chain comprising the amino acid sequence of SEQ ID NO:218, wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.

34. The method of claim 33 , wherein the cancer is pancreatic cancer (PAC).

35. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a binding molecule comprising at least one antigen binding site that binds specifically to TRAILR2 and at least one antigen binding site that binds specifically to CDH17, wherein said binding molecule comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO:212 and (ii) a light chain comprising the amino acid sequence of SEQ ID NO:218, wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.

36. The method of claim 35 , wherein the cancer is pancreatic cancer (PAC).

Priority Claims (1)
EP 17155973 · Feb 14, 2017 · regional
Continuity (3)
Division 15850895 · Dec 21, 2017
Provisional Application 62437770 · Dec 22, 2016
Related Publication 20210095038A1 · Apr 1, 2021